Bladder drug shows promise for dry AMD in new trial
NCT ID NCT07305298
First seen Jan 07, 2026 · Last updated May 19, 2026 · Updated 23 times
Summary
This study tests if Mirabegron, a drug used for overactive bladder, can also help treat dry age-related macular degeneration (AMD). Researchers will compare Mirabegron to another bladder drug (Solifenacin) in 312 people aged 50-80 with both conditions. Participants take the drug daily for 12 months and have checkups every 6 months to measure changes in the retina and vision.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVERACTIVE BLADDER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Federico II
Naples, Italy
Conditions
Explore the condition pages connected to this study.